ABT
Abbott’s screening story gets a fresh stamp of approval
Abbott is back in the colorectal cancer conversation, and this time it’s not because of a flashy launch or a quarterly earnings beat. The company said the American Cancer Society updated its CRC screening guidance and still lists Cologuard and Cologuard Plus as preferred noninvasive options for adults 45 and older at average risk.
Why investors should care
This is less about a science fair ribbon and more about market positioning. When a major medical group keeps your product in the “preferred” lane, it can help with doctor adoption, patient awareness, and the whole payers-will-we-or-won’t-we dance that decides whether a product gets used at scale.
Abbott is also leaning into a broader portfolio angle here, saying it will offer only CRC screening products aligned with the new ACS recommendations. Translation: the company wants its menu to look a lot more like the guideline itself and a lot less like a random buffet.
The bigger picture
Recent publications supporting a Cologuard-first strategy give Abbott extra ammo in the screening debate, especially as health systems keep hunting for options that are easier than a traditional colonoscopy but still useful enough to catch disease early.
For investors, the key question is whether this turns into real volume, not just nice PR. But on days like this, it helps when the medical guideline gods are on your side. Big picture: Abbott just got a helpful reminder that in healthcare, being “preferred” can be worth a lot more than a gold star on the fridge.